The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted ...

Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...

COPENHAGEN, July 7 (Reuters) - Coloplast COLOb.CO has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up to $1.3 billion, ...

Coloplast is a leading global supplier of intimate healthcare products with a strong product portfolio and high market share. The company has a stable business model and benefits from demographic ...

Coloplast reported fiscal fourth-quarter results that included 7% organic revenue growth, driven by 9% growth in both continence care and voice/respiratory. The firm also improved its operating margin ...

Kerecis, the company pioneering the use of sustainably sourced fish skin in cellular therapy and tissue regeneration, today ...